Nurofen Intensive tab. p / o captivity. 200mg + 500mg # 12

Dosage form

Tablets are capsule-shaped, biconvex, film-coated from white to almost white with a pearlescent effect.

Structure

One film-coated tablet contains:

active ingredients: ibuprofen 200 mg and paracetamol 500 mg

excipients: croscarmellose sodium 30 mg, microcrystalline cellulose 120 mg, colloidal silicon dioxide 3 mg, magnesium stearate 5 mg, stearic acid 4 mg.

Shell composition: white film shell 13 mg (polyvinyl alcohol 40%, titanium dioxide 25%, macrogol 20.2%, talc 14.8%), film shell with a pearlescent effect 7 mg (polyvinyl alcohol 47%, talc 27%, macrogol 13.3%, mica-based pearlescent pigment 10% (titanium dioxide 28%, potassium aluminosilicate (E555) 72%), polysorbate 2.7%).

pharmachologic effect

Combined drug, the action of which is due to its constituent components.

Has a directed effect against pain (analgesic), antipyretic and anti-inflammatory effect.

Ibuprofen and paracetamol differ in mechanism and site of action.

As a result of their mutually reinforcing action, a more pronounced decrease in pain sensitivity and an increase in antipyretic action are achieved than separately.

Ibuprofen, a propionic acid derivative from the group of non-steroidal anti-inflammatory drugs (NSAIDs), has anti-inflammatory, anti-edema, analgesic and antipyretic effects.

The mechanism of action of ibuprofen is due to inhibition of the synthesis of prostaglandins - mediators of pain, inflammation and hyperthermic reaction, through the indiscriminate inhibition of cyclooxygenase activity.

1 (COX-1) and cyclooxygenase 2 (COX-2).

The analgesic effect of ibuprofen is provided by its inhibitory effect at the peripheral level.

The antipyretic effect of ibuprofen is associated with a central inhibition of prostaglandin synthesis in the hypothalamus.

Ibuprofen inhibits the migration of leukocytes to the site of inflammation.

In addition, ibuprofen reversibly inhibits platelet aggregation.

Paracetamol is an analgesic non-narcotic agent that has anesthetic, antipyretic and weak anti-inflammatory effect.

Indiscriminately blocks COX-2, mainly in the central nervous system.

Paracetamol can also stimulate the activity of the descending serotonin pathways, which leads to the arrest of the transmission of pain impulses in the spinal cord.

At the peripheral level, paracetamol has a mild effect on COX-1 and COX-2.

The drug has a faster therapeutic effect and more pronounced analgesic effect than ibuprofen and paracetamol alone.

After taking one tablet, the analgesic effect is observed on average 15 minutes after taking the drug, a clinically significant analgesic effect is achieved 40 minutes after taking the drug and lasts for 8 hours.

After taking two tablets, the analgesic effect is observed on average 18 minutes after taking the drug, a clinically significant analgesic effect is achieved 45 minutes after taking the drug and lasts for 9 hours.

Pharmacokinetics

Ibuprofen: absorption is high, rapidly and almost completely absorbed from the gastrointestinal tract (GIT).

Communication with blood plasma proteins - 90%.

It slowly penetrates into the joint cavity, is retained in the synovial fluid, creating higher concentrations in it than in the blood plasma.

It is found in blood plasma 5 minutes after taking the drug on an empty stomach, the maximum concentration (Cmax) in blood plasma is reached in 1-2 hours.

Simultaneous intake with food can reduce the concentration of ibuprofen in the blood plasma and increase the time to reach the maximum concentration (Tmax).

The absorption of ibuprofen is independent of food intake.

It is metabolized in the liver.

After absorption, about 60% of the pharmacologically inactive R-form is slowly transformed into the active S-form.

Half-life

Name ENG

NUROFEN LONG

Clinical and pharmacological group

Analgesic-antipyretic combined composition

ATX code

Ibuprofen in combination with other drugs

Dosage

200mg + 500mg

Structure

One film-coated tablet contains: active ingredients: ibuprofen 200 mg and paracetamol 500 mg

excipients: croscarmellose sodium 30 mg, microcrystalline cellulose 120 mg, colloidal silicon dioxide 3 mg, magnesium stearate 5 mg, stearic acid 4 mg.

Shell composition: white film shell 13 mg (polyvinyl alcohol 40%, titanium dioxide 25%, macrogol 20.2%, talc 14.8%), film shell with a pearlescent effect 7 mg (polyvinyl alcohol 47%, talc 27%, macrogol 13.3%, mica-based pearlescent pigment 10% (titanium dioxide 28%, potassium aluminosilicate (E555) 72%), polysorbate 2.7%).

Indications

Back pain, joint pain, muscle and rheumatic pain, neuralgia, headache, migraine, toothache, painful periods, sore throat, fever, cold and flu symptoms.

The drug is particularly indicated for the symptomatic treatment of pain requiring a more pronounced analgesic effect than ibuprofen or paracetamol alone.

INN / Active ingredient

ibuprofen, paracetamol

Contraindications

Hypersensitivity to ibuprofen, paracetamol or other components of the drug.

Concomitant use of other medicinal products containing paracetamol.

Complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses, and intolerance to acetylsalicylic acid or other NSAIDs (including a history).

Erosive and ulcerative diseases of the gastrointestinal tract (including peptic ulcer and duodenal ulcer, Crohn's disease, ulcerative colitis) or ulcerative bleeding in the active phase or in history (two or more confirmed episodes of peptic ulcer or ulcerative bleeding).

A history of bleeding or perforation of a gastrointestinal ulcer caused by the use of NSAIDs.

Severe liver failure or active liver disease.

Renal failure of severe severity (creatinine clearance < 30 ml / min), confirmed hyperkalemia.

Decompensated heart failure

period after coronary artery bypass grafting.

Cerebrovascular or other bleeding.

Pregnancy (III trimester).

Children up to age 12.

Hemophilia and other blood clotting disorders (including hypocoagulation), hemorrhagic diathesis.,

Carefully,

If you have the conditions listed in this section, you should consult a doctor before using the drug.

Concomitant use of other NSAIDs, a history of a single episode of gastric ulcer or gastrointestinal ulcer bleeding gastritis, enteritis, colitis, presence of Helicobacter pylori infection, ulcerative colitis bronchial asthma or allergic diseases in the stage of exacerbation or in history - the development of bronchospasm is possible systemic lupus erythematosus or mixed connective tissue disease (Sharp's syndrome) - increased risk of aseptic meningitis renal failure, including dehydration (creatinine clearance less than 30-60 ml / min) nephrotic syndrome liver failure frequent alcohol consumption arterial hypertension and / or heart failure, cerebrovascular diseases concomitant use of medicines that may increase the risk of ulceration or bleeding, in particularoral glucocorticosteroids (including prednisolone), anticoagulants (including warfarin), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline) or antiplatelet agents (including acetylsalicylic acid), clopidogregan pregnancy I-II trimester, breastfeeding period elderly age cirrhosis of the liver with portal hypertension, hyperbilirubinemia blood diseases of unknown etiology (leukopenia and anemia), hyperlipidemia, diabetes mellitus, peripheral arterial disease.pregnancy I-II trimester, breastfeeding period elderly age cirrhosis of the liver with portal hypertension, hyperbilirubinemia blood diseases of unknown etiology (leukopenia and anemia), hyperlipidemia, diabetes mellitus, peripheral arterial disease.pregnancy I-II trimester, breastfeeding period elderly age cirrhosis of the liver with portal hypertension, hyperbilirubinemia blood diseases of unknown etiology (leukopenia and anemia), hyperlipidemia, diabetes mellitus, peripheral arterial disease.

Storage conditions and periods

At a temperature not higher than 25 degrees.

Expiration date: 3 years

Specifications

Category

Pain relievers

,

Migraine

Scope of the medicinal product

General

Release form

Tablet

Manufacturer country

Great Britain

Package quantity, pcs

12

Minimum age from

12 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

Nurofen

The amount of the dosage form in the primary package

6 pcs.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Anatomical and therapeutic characteristics

M01AE51 Ibuprofen, in combination with other drugs

Dosage form

Film-coated tablets

Dosage (volume) of the substance in the preparation

ibuprofen 200 mg and paracetamol 500 mg

Expiration date in days

1095

The target audience

Children

Package weight, g

45

Mode of application

:

Read the instructions carefully before taking the drug. < br> For oral administration. For short term use only. < br> Adults and children over 12 years old: 1 tablet up to three times a day with water. The interval between doses of the drug should be at least 6 hours. < br> Maximum single dose: 2 tablets (corresponds to 400 mg ibuprofen, 1000 mg paracetamol). < br> Maximum daily dose for adults: 6 tablets (corresponds to 1200 mg ibuprofen, 3000 mg paracetamol). < br> Maximum daily dose for children 12-18 years old: 4 tablets (corresponds to 800 mg of ibuprofen, 2000 mg of paracetamol). < br> The recommended duration of treatment is no more than 3 days. If, after taking the drug for 2-3 days, the symptoms persist or worsen, you must stop treatment and consult a doctor.

Pharmaco-therapeutic group

:

Combined analgesic (NSAIDs + non-narcotic analgesic)

Information on technical characteristics, delivery set, country of manufacture